Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)

Christian E. Antoni, Arthur Kavanaugh, Bruce Kirkham, Zuhre Tutuncu, Gerd R. Burmester, Udo Schneider, Daniel E. Furst, Jerry Molitor, Edward Keystone, Dafna Gladman, Bernhard Manger, Siegfried Wassenberg, Ralf Weier, Daniel J. Wallace, Michael H. Weisman, Joachim R. Kalden, Josef Smolen

Research output: Contribution to journalArticlepeer-review

615 Scopus citations

Fingerprint

Dive into the research topics of 'Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology